The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...

Merck Animal Health, a division of Merck & Co., Inc. (MRK), Tuesday announced the expansion of Nobivac NXT vaccine platform with the ...

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 ...

TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribetm RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.